title: Therapeutic thrombin injection of pseudoaneurysms: a multicenter experience.
abstract: The standard non-invasive treatment of pseudoaneurysms has been ultrasound-guided compression (UGC). Problems with UGC include pain at the site of compression, long compression times and incomplete closure. Each of these difficulties is exacerbated with large pseudoaneurysms. Recently, ultrasound-guided injection of pseudoaneurysms with thrombin has gained popularity. The goal of this study was to report a multicenter registry using this technique and in so doing detail the clinical utility and safety of this emerging procedure. The medical records of all patients diagnosed with pseudoaneurysm in the vascular laboratory who underwent thrombin injection over the past year were reviewed for patient characteristics and clinical outcome. There were 91 patients (55 male) with a mean age of 69 years. Three patients also had an arteriovenous fistula. The majority of patients were receiving one or more antiplatelet agents and/or anticoagulants. All patients underwent pseudoaneurysm injection with bovine thrombin. The mean aneurysm diameter was 3.3 cm, with a range of 1.5-6.3 cm. Successful thrombosis of the pseudoaneurysm was achieved in 89/91 (98%) of cases. Anticoagulation with heparin was used in one of the unsuccessful cases. In two cases, UGC was used to close a small active region that did not completely thrombose after thrombin injection. There were two patients who had recurrence of pseudoaneurysm the day after successful injection and thrombosis of the pseudoaneurysm. There were no local complications after injection; however, one patient suffered a pulmonary embolus that was thought to be unrelated to the procedure. In conclusion, thrombin injection for the treatment of pseudoaneurysms is safe and effective, even in patients receiving anticoagulation. This procedure should be considered as the initial therapeutic approach for peripheral pseudoaneurysms.
authors.affiliation: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA. mohlere@uphs.upenn.edu
authors.forename: E R
authors.initials: ER
authors.lastname: Mohler
authors.forename: M E
authors.initials: ME
authors.lastname: Mitchell
authors.forename: J P
authors.initials: JP
authors.lastname: Carpenter
authors.forename: D E
authors.initials: DE
authors.lastname: Strandness
authors.forename: M R
authors.initials: MR
authors.lastname: Jaff
authors.forename: J A
authors.initials: JA
authors.lastname: Beckman
authors.forename: M
authors.initials: M
authors.lastname: Gerhard-Herman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017541:Aneurysm, False / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000925:Anticoagulants / Q000627:therapeutic use; D001900:Boston / Q000453:epidemiology; D004219:District of Columbia / Q000453:epidemiology; D004359:Drug Therapy, Combination; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010414:Pennsylvania / Q000453:epidemiology; D013917:Thrombin / Q000627:therapeutic use*; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex; D014861:Washington / Q000453:epidemiology
chemical_list: D000925:Anticoagulants; D006490:Hemostatics; D013917:Thrombin